Heat shock protein 70-derived B29 epitope (B29 epitope)

The B29 epitope is a conserved peptide derived from heat shock protein 70 (HSP70), first identified in mycobacterial HSP70 and present with minor variations in mammalian homologs (e.g., HSPA1A, HSPA9). Immunization with the B29 peptide in preclinical (mouse) models reliably induces antigen-specific regulatory T cells (CD4^+^CD25^+^FoxP3^+^), which suppress autoimmune disease progression and inflammation. The underlying mechanism involves classical MHC class II presentation, expansion of Treg populations, and secretion of anti-inflammatory cytokines. Tregs induced by B29 can persist long-term in tissues and effectively inhibit disease activity, a phenomenon that can be reversed by Treg depletion. The B29 epitope's evolutionary conservation and cross-reactivity with mammalian HSP70 peptides facilitate immune tolerance to self-antigens, positioning it as a candidate therapeutic target for tolerogenic vaccines in chronic inflammatory and autoimmune disease settings.

Other names

B29 peptideHSP70 B29 epitopemB29amB29b (mammalian homologs)HSP70-derived immunoregulatory peptide

Peptide immunization leads to expansion of CD4^+^CD25^+^FoxP3^+^ regulatory T cells These Tregs suppress effector T cell responses and inflammation by producing anti-inflammatory cytokines (e.g., IL-10, IL-35) Likely MHC class II-restricted presentation of B29 peptide to Tregs Cross-reactivity with mammalian HSP70 homologs aids in tolerance to self